Vericel websites use cookies, small text files stored on your browser, to personalize your web experience and to analyze website traffic. By continuing to use this website without changing your settings, you are agreeing to our use of cookies and to our collection of information. For more information about what Vericel collects and how we use it, visit our Privacy Policy.
Total Revenues of $14.1 Million Reported for the Quarter Carticel and Epicel Revenues Increase 31% versus First Quarter 2015 Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., May 10, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific
Record Quarterly Product Revenues of $31.3 Million Represent a 41% Increase Over Fourth Quarter 2017 Full-Year 2018 Product Revenues of $90.9 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in
Full Year 2019 Product Revenues of $117.9 Million Increased 30% Over 2018 Record Quarterly Revenue and Profit in the Fourth Quarter Conference Call Today at 8:30am Eastern Standard Time CAMBRIDGE, Mass., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced
Record Fourth Quarter Total Revenue, Gross Margin, Net Income and Operating Cash Flow Full-Year 2021 Total Revenue Expected to Grow 30%-32% to Approximately $161 to $164 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation
Full-Year 2021 Total Revenue Growth of 26% Full-Year 2022 Total Revenue Guidance of $178 to $189 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and
Record Fourth Quarter Total Revenue of $52.7 Million and 31% Net Income Growth Full-Year 2022 Total Revenue of $164.4 Million, with MACI Revenue of $132 Million Full-Year 2023 Total Revenue Guidance of $180 to $188 Million, with MACI Revenue of $152 to $156 Million Conference Call Today at 8:30am
Full-Year 2023 Total Revenue Growth of 20% to $197.5 Million, with Adjusted EBITDA Growth of 40% Fourth Quarter Total Revenue Growth of 23% to $65.0 Million, with Adjusted EBITDA Growth of 50% Fourth Quarter Gross Margin of 75% and Adjusted EBITDA Margin of 34% Full-Year 2024 Total Revenue Guidance
Record Quarterly Revenues of $23.4 Million Represent a 41% Increase Over Fourth Quarter 2016 Positive Operating and Net Income Reported for the Fourth Quarter Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass. , March 05, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a
Total Revenues of $14.7 Million Reported for the Fourth Quarter Conference Call Today at 4:30pm Eastern Time CAMBRIDGE, Mass., March 23, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe
